AU2020282707B2 - Tricyclic compounds - Google Patents

Tricyclic compounds Download PDF

Info

Publication number
AU2020282707B2
AU2020282707B2 AU2020282707A AU2020282707A AU2020282707B2 AU 2020282707 B2 AU2020282707 B2 AU 2020282707B2 AU 2020282707 A AU2020282707 A AU 2020282707A AU 2020282707 A AU2020282707 A AU 2020282707A AU 2020282707 B2 AU2020282707 B2 AU 2020282707B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
unsubstituted
compound
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2020282707A
Other languages
English (en)
Other versions
AU2020282707A1 (en
Inventor
Sandrine Vendeville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aligos Therapeutics Inc
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of AU2020282707A1 publication Critical patent/AU2020282707A1/en
Application granted granted Critical
Publication of AU2020282707B2 publication Critical patent/AU2020282707B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020282707A 2019-05-30 2020-05-27 Tricyclic compounds Expired - Fee Related AU2020282707B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854597P 2019-05-30 2019-05-30
US62/854,597 2019-05-30
PCT/US2020/034746 WO2020243199A1 (en) 2019-05-30 2020-05-27 Tricyclic compounds

Publications (2)

Publication Number Publication Date
AU2020282707A1 AU2020282707A1 (en) 2021-12-02
AU2020282707B2 true AU2020282707B2 (en) 2025-06-19

Family

ID=73552666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020282707A Expired - Fee Related AU2020282707B2 (en) 2019-05-30 2020-05-27 Tricyclic compounds

Country Status (19)

Country Link
US (1) US11136321B2 (https=)
EP (1) EP3976618A4 (https=)
JP (1) JP2022534501A (https=)
KR (1) KR20220016177A (https=)
CN (1) CN113906029A (https=)
AU (1) AU2020282707B2 (https=)
BR (1) BR112021023967A2 (https=)
CA (1) CA3138938A1 (https=)
CL (1) CL2021003139A1 (https=)
CO (1) CO2021017202A2 (https=)
EA (1) EA202192760A1 (https=)
IL (1) IL287813A (https=)
MA (1) MA56058A (https=)
MX (1) MX2021014458A (https=)
PE (1) PE20220427A1 (https=)
PH (1) PH12021552953A1 (https=)
SG (1) SG11202113214QA (https=)
TW (1) TW202110845A (https=)
WO (1) WO2020243199A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220000874A1 (en) * 2019-05-30 2022-01-06 Aligos Therapeutics, Inc. Tricyclic compounds
TWI886184B (zh) * 2019-12-10 2025-06-11 大陸商上海翰森生物醫藥科技有限公司 含吡唑多環類衍生物抑制劑、其製備方法和應用
GB202103704D0 (en) * 2021-03-17 2021-04-28 Pathios Therapeutics Ltd Compounds
EP4251625A4 (en) * 2020-11-24 2024-10-09 Aligos Therapeutics, Inc. Tricyclic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
AU2013404035B2 (en) * 2013-10-29 2017-04-20 Medivir Ab Quinazoline based respiratory syncytial virus inhibitors
CO2018009382A2 (es) 2016-03-09 2018-09-20 Univ Emory Eliminación del virus de la hepatitis b con agentes antivirales
CN110066278B (zh) * 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FANG, Z. ET AL.: "Discovery of pyrazolo [1, 5-a] pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 27, no. 14, 2017, pages 3201 - 3204. *

Also Published As

Publication number Publication date
WO2020243199A1 (en) 2020-12-03
MA56058A (fr) 2022-04-06
EP3976618A4 (en) 2023-01-04
US11136321B2 (en) 2021-10-05
KR20220016177A (ko) 2022-02-08
PH12021552953A1 (en) 2022-07-25
SG11202113214QA (en) 2021-12-30
JP2022534501A (ja) 2022-08-01
BR112021023967A2 (pt) 2022-03-08
EA202192760A1 (ru) 2022-03-05
PE20220427A1 (es) 2022-03-29
MX2021014458A (es) 2022-01-06
EP3976618A1 (en) 2022-04-06
CL2021003139A1 (es) 2022-09-23
CN113906029A (zh) 2022-01-07
AU2020282707A1 (en) 2021-12-02
US20200407361A1 (en) 2020-12-31
TW202110845A (zh) 2021-03-16
IL287813A (en) 2022-01-01
CO2021017202A2 (es) 2022-01-17
CA3138938A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
AU2020282707B2 (en) Tricyclic compounds
JP5978317B2 (ja) 新規なインドリジン化合物、それらの調製方法及びそれらを含有する医薬組成物
JP7203816B2 (ja) １，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン類似体
AU2004290643B2 (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with PDE-5 inhibiting activity
JP5642777B2 (ja) Ｉａｐ阻害剤
CN105579450B (zh) 新的吲嗪化合物、其制备方法和包含它们的药物组合物
JP6395829B2 (ja) 新規イソインドリン又はイソキノリン化合物、それらの調製のためのプロセス及びそれらを含有する医薬組成物
BR112014022271B1 (pt) Compostos com base em imidazo[1,2-b]piridazina, composições compreendendo-os, e usos dos mesmos
ES2349476T3 (es) Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
WO2015077193A1 (en) Inhibitors of lysine methyl transferase
JP2020524148A (ja) 置換５−シアノインドール化合物及びその使用
PT2252611E (pt) (di-hidro)pirrolo[2,1-a]isoquinolinas
CA3197470A1 (en) Bicyclic compounds
WO2023178035A1 (en) Multicyclic compounds
ES2208404T3 (es) Derivados de imidazo-triazina como ligandos de los receptores de3 gaba.
KR20220002971A (ko) 바이사이클릭 및 트라이사이클릭 화합물
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
JP2012528168A (ja) Ｉａｐ阻害剤
JP2009513640A (ja) Ｈｉｖインテグラーゼインヒビター
TW509692B (en) 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones
US20220000874A1 (en) Tricyclic compounds
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
TW202547470A (zh) 作為KCa3.1鉀通道阻斷劑之氮雜吲哚啉酮化合物

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee